IRIS
VICENTI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 979
NA - Nord America 749
EU - Europa 217
SA - Sud America 214
AF - Africa 54
OC - Oceania 1
Totale 2.214
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 679
BD - Bangladesh 241
CN - Cina 218
SG - Singapore 193
IT - Italia 175
BR - Brasile 133
HK - Hong Kong 114
VN - Vietnam 77
IN - India 32
AR - Argentina 28
MX - Messico 25
CA - Canada 23
IQ - Iraq 18
EC - Ecuador 17
PK - Pakistan 16
ZA - Sudafrica 13
ID - Indonesia 12
CO - Colombia 11
SA - Arabia Saudita 11
RU - Federazione Russa 10
CL - Cile 9
TR - Turchia 9
UZ - Uzbekistan 8
MA - Marocco 7
PH - Filippine 7
PY - Paraguay 7
VE - Venezuela 7
TN - Tunisia 6
EG - Egitto 4
ES - Italia 4
FR - Francia 4
IL - Israele 4
MY - Malesia 4
PL - Polonia 4
CH - Svizzera 3
CR - Costa Rica 3
DE - Germania 3
DZ - Algeria 3
NL - Olanda 3
AT - Austria 2
BZ - Belize 2
CG - Congo 2
DO - Repubblica Dominicana 2
GB - Regno Unito 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
JO - Giordania 2
MR - Mauritania 2
NE - Niger 2
PR - Porto Rico 2
SN - Senegal 2
TH - Thailandia 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
CD - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
CV - Capo Verde 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GN - Guinea 1
GP - Guadalupe 1
HR - Croazia 1
IE - Irlanda 1
JP - Giappone 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LC - Santa Lucia 1
LY - Libia 1
ME - Montenegro 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PG - Papua Nuova Guinea 1
PS - Palestinian Territory 1
SD - Sudan 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
Totale 2.214
Salva come PNG Salva come JPEG
Città #
San Jose 362
Beijing 119
Ashburn 114
Hong Kong 110
Singapore 87
Milan 36
New York 30
Ho Chi Minh City 29
Santa Clara 27
Mexico City 17
Rome 14
Hanoi 11
Los Angeles 11
Figino 10
Naples 9
São Paulo 9
Baghdad 8
Tashkent 8
Bari 7
Buffalo 7
Rio de Janeiro 7
Riyadh 7
Salvador 7
Biên Hòa 6
Quito 6
Toronto 6
Turin 6
Bogotá 5
Casablanca 5
Mumbai 5
Thái Bình 5
Atlanta 4
Brasília 4
Catania 4
Chennai 4
Guarulhos 4
Guayaquil 4
Ningbo 4
Asunción 3
Belo Horizonte 3
Cairo 3
Campinas 3
Can Tho 3
Charlotte 3
Chicago 3
Delhi 3
Dietikon 3
Durban 3
Haiphong 3
Istanbul 3
Itaquaquecetuba 3
Jeddah 3
Johannesburg 3
Medellín 3
Ninh Bình 3
Orem 3
Pretoria 3
Taboão da Serra 3
Ahmedabad 2
Ambato 2
Amman 2
Barcelona 2
Bengaluru 2
Bologna 2
Bình Dương 2
Camaçari 2
Cape Town 2
Caracas 2
Council Bluffs 2
Cuenca 2
Curitiba 2
Córdoba 2
Da Nang 2
Dakar 2
Denpasar 2
Detroit 2
Erbil 2
Genoa 2
Itajaí 2
Machala 2
Manaus 2
Manchester 2
Manila 2
Marseille 2
Messina 2
Miami 2
Mogi das Cruzes 2
Najaf 2
Newark 2
Niamey 2
Ottawa 2
Padua 2
Peshawar 2
Santiago 2
Shanghai 2
St Petersburg 2
Tel Aviv 2
Tigre 2
Tunis 2
Valencia 2
Totale 1.262
Salva come PNG Salva come JPEG
Nome #
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 95
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 81
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 71
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 71
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 64
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 42
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 38
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 35
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines 33
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 32
Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm) 31
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties 31
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 31
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 30
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes 29
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 29
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3 29
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 29
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 28
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 28
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020 28
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 28
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 28
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021 27
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 27
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 26
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 26
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 26
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 25
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 25
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 24
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 24
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 24
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 24
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 24
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 24
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 24
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 23
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 23
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 23
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 23
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 23
Serendipitous identification of azine anticancer agents using a privileged scaffold morphing strategy 22
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 22
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 22
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 21
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 20
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 20
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype 20
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 20
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 20
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 20
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 20
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 20
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 20
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 19
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting 19
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 19
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 19
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 19
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 19
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 19
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 19
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 19
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 18
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 18
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 18
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 18
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 18
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 17
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects 17
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 17
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 17
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1 17
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 17
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 17
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France) 17
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 17
Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting 16
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication 16
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 16
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 16
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 15
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 15
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 14
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 14
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 14
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination 14
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 13
Serum neutralizing activity against b.1.1.7, b.1.351, and p.1 sars-cov-2 variants of concern in hospitalized covid-19 patients 13
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 12
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 10
Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era 9
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 9
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens 8
Totale 2.311
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.042
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.042
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20254 0 0 0 1 0 0 0 1 0 1 0 1
2025/20262.149 83 15 218 143 141 103 54 108 574 234 250 226
2026/2027158 158 0 0 0 0 0 0 0 0 0 0 0
Totale 2.311